ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose 28 June 2021 A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.

Es gaben so viele gute news heut! 👏

Das wehre schön

Die soll entiich auf 180 steigen. Langsam oder schnell mir egal 😎

Hoffentlich 🍻

Heute fällt die 100

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer 24 June 2021 AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal agent (abiraterone, enzalutamide).

Jahaa Adler ist super alder! Lambo schon bestellt und jetzt geh weiter zum Neovacs Forum...

Adler Modemarrkt geht gerade ab gute Dip zum kaufen

HUTCHMED and AstraZeneca collaboration In 2011, HUTCHMED and AstraZeneca entered a global licensing agreement with respect to the development and commercialization of savolitinib. HUTCHMED is responsible for the manufacturing and supply of savolitinib, and AstraZeneca is responsible for its commercialization in China and worldwide.

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

Zudem wurde bereits widersprochen - Das Paul-Ehrlich-Institut gibt bei der festgestellten Verunreinigung des Astrazeneca-Impfstoffs Entwarnung. Die von Ulmer Forschenden nachgewiesenen Eiweiße haben demnach keine Auswirkungen.

Alte Sache mbhpro

Das wird meiner Meinung nach gar nicht wahrgenommen...

https://www.scinexx.de/news/medizin/verunreinigungen-im-astrazeneca-impfstoff/

22 June 2021 AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.